The request arrives in some version of this sentence: “I don’t have wrinkles yet, and I want to keep it that way.” The patient is in her mid-twenties, she has seen prevention content on social media, and she wants a neuromodulator, a skin booster, or both. The clinical question is which parts of prevention are supported by evidence.
It does not resolve the way most published content implies. The strongest preventive evidence sits with photoprotection and topical retinoids — unglamorous, cheap, backed by randomized data and an FDA-approved label. The thinnest sits with the intervention patients ask for by name: no randomized trial has ever tested whether starting botulinum toxin young prevents future wrinkles.
Prevention-first care is also the part of Korean aesthetic culture that crossed into US clinics most cleanly, because unlike polynucleotides or exosome products it needs nothing unavailable here. It is a way of sequencing care, not a product — one thread in how Korean aesthetic practice is reshaping US clinics.
What “prejuvenation” means, and what Korean practice contributed
“Prejuvenation” is a press and industry term, not a clinical one: no diagnostic definition, no validated endpoint, no outcome measure. What it names is an intent: intervening early to slow visible change rather than correcting it later. Useful shorthand with patients, and nothing more.
The Korean contribution is a mindset, not a shopping list. Korean English-language press describes a culture built on routine rather than one-off correction: the Korea Times reports that “the emphasis has shifted from correction to prevention,” and that booking a laser or a skin booster is now almost as routine as booking a haircut. That is journalism describing a market, not evidence that Korean protocols produce better outcomes. What transfers is the habit set — skin quality treated first, cadence rather than events, modalities layered deliberately.
Empire teaches that sequencing at the faculty level. At the Empire Holiday Gala on Thursday, December 3, 2026 in New York City, Dr. Lanna Cheuck, DO, FACS gives a live stage demonstration — Dr. Lanna’s Celebrity Non-Surgical Facelift™, The Multilayer K-Beauty Stack — described on Empire’s page as inspired by advanced Korean aesthetic principles: injectables, collagen biostimulators, energy-based devices and regenerative therapies sequenced to the patient’s anatomy rather than relying on excessive filler, plus an LHALA Peel and a customized skin-tox mesotherapy treatment.
Tier one: photoprotection and retinoids
Daily sunscreen
One randomized trial has tested sunscreen against skin aging, the 2013 analysis from the Nambour trial in subtropical Queensland: adults assigned to daily broad-spectrum sunscreen showed no detectable increase in skin aging over 4.5 years, while adults left to use sunscreen at their own discretion did.
State the much-quoted “24%” precisely, because nearly every version in circulation is wrong. It is a relative odds figure — relative odds 0.76 (95% CI 0.59 to 0.98) of moving up a photoaging grade — comparing daily sunscreen use with discretionary sunscreen use. It is not 24% less wrinkling, not 24% younger-looking skin, and not a comparison against no sunscreen: both arms had sunscreen, and reported sun exposure was similar. Blinded assessors graded silicone casts of the back of the left hand on a microtopography scale, not the face. The analysis covered the 903 participants under 55, and only 604 gave a usable cast at both time points.
The defensible claim is narrower than the meme and still worth leading with: consistent daily use beat as-you-feel-like-it use on an objective measure, in high-UV conditions. The honest gap is that no randomized trial of daily sunscreen with a validated facial photoaging endpoint has been published.
Topical tretinoin
Tretinoin is the other tier-one intervention and the only topical with an FDA-approved photoaging indication. Get the product right: Renova tretinoin emollient cream 0.05% held the broader indication but is discontinued in Drugs@FDA. The marketed product is Renova 0.02%, labeled for mitigation, or palliation, of fine facial wrinkles only — it states it has not demonstrated an effect on coarse wrinkling, tactile roughness or mottled hyperpigmentation.
The label also does your expectation-setting, in capital letters: tretinoin “DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN.” It is approved only as an adjunct to comprehensive skin care and sun avoidance with at least SPF 15 sunscreen. In the pivotal 24-week vehicle-controlled trial of the 0.05% cream, 68% of 296 subjects improved globally versus 43% on vehicle — sit with that 43%, because nearly half the vehicle arm improved on emollient plus sun avoidance alone.
“Preventative” neuromodulators: what the evidence supports and what it does not
Botox® Cosmetic is FDA-approved and the approved population is adults. Two corrections matter, because this circulates wrong in both directions. The current label, published January 2026, reads “indicated in adult patients” with no upper age limit, while the 2002 and 2009 labels read “adult patients 65 years of age or younger.” Neither contains an approved range of 18 to 65, and pediatric safety and effectiveness have not been established.
The approved indications are moderate to severe glabellar lines, lateral canthal and forehead lines, and platysma bands. A 26-year-old with nothing of at least moderate severity is outside them, so treating her is off-label use of an approved product — legitimate, but name it in the consent discussion rather than implying the label covers prevention. Nor is there a minimum-age evidence base: the registration trials enrolled adults who already had at-least-moderate lines at maximum frown, mean age 46, and no randomized prospective trial of botulinum toxin begun in wrinkle-free young adults appears in the literature.
What exists instead is weaker by design. A 2023 review and practitioner survey found a paucity of high-quality research in younger adults and concluded the literature supports the toxin for correcting lines, not preventing them; a 2025 systematic review found the data heterogeneous and long-term outcomes unestablished.
The most-cited piece of prevention evidence is a 2006 case report on 38-year-old identical twins: imprinted forehead and glabellar lines visible at rest were absent in the twin treated two to three times a year for 13 years and present in her sister. Two caveats. The comparison twin was not untreated — she had been injected twice, and the paper’s own term is the “minimally treated twin.” And it is one twin pair: an unblinded, uncontrolled case report. Not evidence of population benefit, and not something to show a patient.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
The only work that attempted the long-horizon question points the other way: a computational digital-twin study found any wrinkle-depth advantage from starting in the twenties had disappeared by year 15 — a simulation, with no patients treated, so not clinical evidence. Long-term safety data are reassuring but narrow: no tachyphylaxis and no rise in adverse events across years of repeated abobotulinumtoxinA cycles, in patients treated for lines they already had.
None of this makes conservative neuromodulator work wrong; it makes the framing wrong. Empire’s article on low-dose neuromodulator technique covers restrained dosing, and the piece on the overtreated look covers the other end of the same consultation. Sell softening of a line the patient already makes, not a future she has not been shown to be buying.
What prevention-first care can defensibly mean
The useful version is a shift in what you treat first: barrier integrity, pigment evenness, texture and collagen support on a maintenance cadence, instead of waiting to correct volume loss a decade later. Layering is not evidence-based, though. No trial compares a multi-step routine against a simple one for appearance outcomes, and patch-test surveillance shows product-related contact dermatitis rising more than 2.7-fold over two decades. In 8- to 17-year-olds, routines get more complex while daily SPF use stays suboptimal — the step with the real evidence is the one being skipped.
In office, expect moderate, repeatable improvement rather than transformation. A 2026 meta-analysis of 38 studies found laser resurfacing and chemical peeling comparably effective, with lasers needing fewer sessions and causing more pain. Microneedling’s headline 83% is pooled patient-reported satisfaction at level IV evidence, not a texture effect size. Intradermal hyaluronic acid sits in the same bracket: SKINVIVE™ by Juvéderm® is approved to improve skin smoothness of the cheeks in adults over 21 and to reduce neck lines, not for “glow” or whole-face use, and its pivotal trial compared treatment against no treatment. More in the comparison of skin boosters and traditional dermal fillers and in the clinical science behind “glass skin”.
The demand signal, read honestly
In the AAFPRS 2025 member survey, 57% of surgeons reported an increase in patients under 30 requesting cosmetic procedures or injectables, many opting for subtle, preventative approaches. That is a December 2025 online opinion survey of a select group of members, with no published sample size: it measures perception, not patients. The counterweight: in the ASPS 2025 report, cosmetic surgery fell 9% among patients 18 to 25 and 5% among those 26 to 35 while rising 24% in patients 66 and older, and ASPS publishes no age breakdown for neuromodulators at all.
The concern mix is steadier. In the 2025 ASDS survey of more than 3,500 consumers — a consumer survey, never to be merged with member figures — skin texture and discoloration tied with lines around and under the eyes at 78% as the leading facial concerns. Build the early conversation around that, and see how Korean aesthetic philosophy is reshaping patient expectations for the operational side.
Patient selection, screening and the obligation to defer
Younger, social-media-driven requests raise the base rate of patients you should not treat, which makes screening part of the service. The best prevalence estimates put body dysmorphic disorder at 1.9% in community adults against 13.2% in general cosmetic surgery, 20.1% in rhinoplasty and 9.2% in cosmetic dermatology outpatients — and the same review notes it is poorly identified in exactly those settings. A critical review of cosmetic outcomes concludes that most patients with the disorder do poorly after intervention.
Be precise about causation: a systematic review of 22 studies on photo editing and body concerns found mixed, inconsistent associations. Say associations are inconsistent; do not say filters cause body dysmorphia. Dermatology journals are publishing ethics commentary on prevention-first care and adolescent injectables, and the recommendations are practical: validated BDD screening, structured counselling, and a cooling-off period rather than same-day conversion.
Now the part no marketing page prints: some of these patients should be deferred and some declined. A patient with no visible change at rest, a concern that does not match what you can see, a fixation traceable to a filtered photograph, or a belief that a procedure prevents aging, is one to educate, re-book or refer — not to treat because she is willing to pay. Declining is a clinical decision, not lost revenue. Consent for early intervention should also state plainly that preventive benefit in a patient without established lines has not been shown in a randomized trial.
Frequently asked questions
What is “prejuvenation”?
A press and industry term for intervening early, usually in the twenties and thirties, to slow visible aging rather than correct it later. It is not a diagnosis or a validated endpoint, so tie each claim underneath it to the evidence for that intervention.
Does preventative Botox work?
It works for what it is approved to do: temporarily improving the appearance of lines associated with muscle activity in adults who have them. Whether starting young prevents future wrinkles is unknown — no randomized trial has tested prevention in young patients, and the support is one identical-twin case report, retrospective series and expert opinion.
At what age should treatment start?
No evidence base sets a starting age and no label sets one; Botox Cosmetic is indicated in adult patients, and its registration trials enrolled adults with existing moderate-to-severe lines at a mean age of 46. Sunscreen and a retinoid can start as soon as a patient will use them, while injectable decisions should follow findings on the face rather than a birthday.
Is prevention-first care evidence-based?
Partly, and the parts are not equal: photoprotection has a randomized trial behind it, and tretinoin has randomized trials plus an FDA-approved indication for mitigating fine facial wrinkles alongside sun avoidance. Peels, microneedling and intradermal hyaluronic acid have moderate evidence for texture, and “preventative” neuromodulator use is the weakest link.
How do you handle a young patient asking for injectables?
Examine at rest and in animation, document what is present, and separate what you can treat from what she is asking you to prevent. Screen for body dysmorphic disorder with a validated instrument and ask what prompted the request. Offer photoprotection, a retinoid and barrier care as the genuinely preventive part of the plan, and if the findings do not support treatment, defer or decline and record why.
Where to learn this properly
A prevention-first service line runs on skin: procedural skin skills, plus the judgment to sequence and to decline. Empire’s Complete Facial Aesthetic Training includes medical-grade chemical peels and microneedling — the modalities carrying most of the early skin-quality work above, and the ones patients asking for “prevention” are often better served by than by a neuromodulator. The background on choosing chemical peel classes and microneedling training sets out what a hands-on course should include.
